menu
    • menu
    [{"orgOrder":0,"company":"Biogenea Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GREECE","productType":"Vaccine","year":"2026","type":"Inapplicable","leadProduct":"Gynorylaq","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Biogenea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biogenea Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biogenea Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Biogenea Pharmaceuticals","sponsor":"Interbalkan Medical Center, Thessaloniki, Greece","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GREECE","productType":"Vaccine","year":"2026","type":"Inapplicable","leadProduct":"Colonyvaq-CRC","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Biogenea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biogenea Pharmaceuticals \/ Interbalkan Medical Center, Thessaloniki, Greece","highestDevelopmentStatusID":"6","companyTruncated":"Biogenea Pharmaceuticals \/ Interbalkan Medical Center, Thessaloniki, Greece"}]

    Find Clinical Drug Pipeline Developments & Deals by Biogenea Pharmaceuticals

    Menu

    Biogenea Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Biogenea Pharmaceuticals

                            Greece arrow
                            VMX
                            Not Confirmed

                            Biogenea Pharmaceuticals

                            Greece arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Colonyvaq-CRC,Capecitabine,Oxaliplatin,5 -Fluorouracil,Calcium Folinate,Nivolumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Interbalkan Medical Center, Thessaloniki, Greece

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            COLONYVAQ™, a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS Stage III Colorectal Cancer

                            Details : Colonyvaq-CRC is a Vaccine drug, which is currently being evaluated in Phase I clinical studies for the treatment of Colorectal Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            January 08, 2026

                            Lead Product(s) : Colonyvaq-CRC,Capecitabine,Oxaliplatin,5 -Fluorouracil,Calcium Folinate,Nivolumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Interbalkan Medical Center, Thessaloniki, Greece

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Biogenea Pharmaceuticals

                            Greece arrow
                            VMX
                            Not Confirmed

                            Biogenea Pharmaceuticals

                            Greece arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gynorylaq

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            GYNORYLAQ™-VLINIVAL™: Quantum-Entangled |Ψ⟩-Guided Personalized Neoantigenic Peptide Vaccination in Hig...

                            Details : Gynorylaq is a Vaccine drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Endometrial Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            January 05, 2026

                            Lead Product(s) : Gynorylaq

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            • Privacy policy
                            • Terms and conditions
                            • Disclaimers
                            • LinkedIn
                            • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.